Composition containing sumo inhibitor and application

US11541032B2 · kind B2 · utility

Assignee

• CHINA PHARMACEUTICAL UNIVERSITY · CN

Inventors

• Haiping HAO · Nanjing, CN
• Hong Wang · Beijing, CN
• Jiyu Zhou · Nanjing, CN
• Guangji Wang · Sichuan, CN
• Shuang CUI · Nanjing, CN
• Xiaojie PAN · Nanjing, CN
• Yitong Guo · Beijing, CN
• Ningning Huang · Nanjing, CN

Key dates

• Filing date: Nov 22, 2019
• Grant date: Jan 3, 2023
• Expiry date: Jul 18, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P1/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.